Design and validation of a histological scoring system for nonalcoholic fatty liver disease

被引:8611
作者
Kleiner, DE
Brunt, EM
Van Natta, M
Behling, C
Contos, MJ
Cummings, OW
Ferrell, LD
Liu, YC
Torbenson, MS
Unalp-Arida, A
Yeh, M
McCullough, AJ
Sanyal, AJ
机构
[1] NCI, Pathol Lab, Bethesda, MD 20892 USA
[2] St Louis Univ, Sch Med, Dept Pathol, Ctr Liver, St Louis, MO 63104 USA
[3] Johns Hopkins Ctr Clin Trials, Baltimore, MD USA
[4] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
[5] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA USA
[6] Univ Hosp, Dept Pathol, Indianapolis, IN USA
[7] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA
[8] Metrohlth Med Ctr, Dept Pathol, Cleveland, OH USA
[9] Metrohlth Med Ctr, Div Gastroenterol, Cleveland, OH USA
[10] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA
[11] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA
[12] Virginia Commonwealth Univ, Med Ctr, Dept Internal Med, Div Internal Med,Div Gastroenterol, Richmond, VA USA
关键词
D O I
10.1002/hep.20701
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of a history of significant alcohol use or other known liver disease. Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD. The Pathology Committee of the NASH Clinical Research Network designed and validated a histological feature scoring system that addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity score (NAS) for use in clinical trials. The scoring system comprised 14 histological features, 4 of which were evaluated semi-quantitatively: steatosis (0-3), lobular inflammation (0-2), hepatocellular ballooning (0-2), and fibrosis (0-4). Another nine features were recorded as present or absent. An anonymized study set of 50 cases (32 from adult hepatology services, 18 from pediatric hepatology services) was assembled, coded, and circulated. For the validation study, agreement on scoring and a diagnostic categorization ("NASH," "borderline," or "not NASH") were evaluated by using weighted kappa statistics. Inter-rater agreement on adult cases was: 0.84 for fibrosis, 0.79 for steatosis, 0.56 for injury, and 0.45 for lobular inflammation. Agreement on diagnostic category was 0.61. Using multiple logistic regression, five features were independently associated with the diagnosis of NASH in adult biopsies: steatosis (P =.009), hepatocellular ballooning (P =.0001), lobular inflammation (P =.0001), fibrosis (P =.0001), and the absence of lipogranulomas (P =.001). The proposed NAS is the unweighted sum of steatosis, lobular inflammation, and hepatocellular ballooning scores. In conclusion, we present a strong scoring system and NAS for NAFLD and NASH with reasonable inter-rater reproducibility that should be useful for studies of both adults and children with any degree of NAFLD. NAS of >= 5 correlated with a diagnosis of NASH, and biopsies with scores of less than 3 were diagnosed as "not NASH."
引用
收藏
页码:1313 / 1321
页数:9
相关论文
共 27 条
[1]   IDIOPATHIC STEATOHEPATITIS IN CHILDHOOD - A MULTICENTER RETROSPECTIVE STUDY [J].
BALDRIDGE, AD ;
PEREZATAYDE, AR ;
GRAEMECOOK, F ;
HIGGINS, L ;
LAVINE, JE .
JOURNAL OF PEDIATRICS, 1995, 127 (05) :700-704
[2]   OBSERVER VARIATION IN ASSESSMENT OF LIVER BIOPSIES OF ALCOHOLIC PATIENTS [J].
BEDOSSA, P ;
POYNARD, T ;
NAVEAU, S ;
MARTIN, ED ;
AGOSTINI, H ;
CHAPUT, JC .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1988, 12 (01) :173-178
[3]   Grading and staging the histopathological lesions of chronic hepatitis. The Knodell histology activity index and beyond [J].
Brunt, EM .
HEPATOLOGY, 2000, 31 (01) :241-246
[4]   Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions [J].
Brunt, EM ;
Janney, CG ;
Di Bisceglie, AM ;
Neuschwander-Tetri, BA ;
Bacon, BR .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (09) :2467-2474
[5]  
Brunt EM, 2004, SEMIN LIVER DIS, V24, P3
[6]   Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease [J].
Caldwell, SH ;
Oelsner, DH ;
Iezzoni, JC ;
Hespenheide, EE ;
Battle, EH ;
Driscoll, CJ .
HEPATOLOGY, 1999, 29 (03) :664-669
[7]  
Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1111/j.1572-0241.2003.07486.x
[8]  
Day C P, 2002, J Gastroenterol Hepatol, V17 Suppl 3, pS377, DOI 10.1046/j.1440-1746.17.s3.31.x
[9]  
DIGGLE PJ, 1995, ANAL LONGITUDINAL DA
[10]   Non-alcoholic steatohepatitis: What is it, and why is it important in the Asia-Pacific region? [J].
Farrell, GC .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 18 (02) :124-138